Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

September 23, 2025

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Aditya Bardia, MD, MPH, FASCO; and Erika P. Hamilton, MD, discuss recent efficacy and safety data of TROP2-targeted antibody-drug conjugate (ADC) plus immune checkpoint inhibitor combinations for advanced triple-negative breast cancer (TNBC).

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Describe the mechanistic rationale for utilizing ADCs to target TROP2 in the management of patients with metastatic TNBC
Evaluate recent evidence supporting the evolving role of ADCs in the management of patients with metastatic TNBC

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Faculty:

Aditya Bardia, MD, MPH, FASCO

Professor of Medicine, Geffen School of Medicine
Program Director, Breast Medical Oncology
Assistant Chief, Translational Research, Division of Hematology-Oncology
Director, Translational Research Integration
UCLA Health Jonsson Comprehensive Cancer Center
University of California, Los Angeles
Los Angeles, CA

Disclosures: Consultant: Alyssum, Daiichi Sankyo/AstraZeneca, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer; Research (paid to institution): Alyssum, Daiichi Sankyo/AstraZeneca, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer.

Erika P. Hamilton, MD

Director, Breast Cancer Research Program
Chair, Breast Executive Committee
Sarah Cannon Research Institute
Nashville, TN

Disclosures: Consultant (all payments to institution): Accutar Biotechnology, Arvinas, AstraZeneca, BeiGene, Circle Pharma, Daiichi Sankyo, Entos, Gilead Sciences, Halda Therapeutics, Incyclix Bio, IQVIA, Janssen, Jazz Pharmaceuticals, Jefferies LLC, Johnson and Johnson, Lilly, Medical Pharma Services, Mersana, Novartis, Pfizer, Pyxis Oncology, Roche/Genentech, Samsung Bioepis, Shorla Pharma, Stemline Therapeutics, Tempus Labs, Zentalis Pharmaceuticals; Research Funding (all payments to institution): AbbVie, Acerta Pharma, Accutar Biotechnology, ADC Therapeutics, AKESOBIO Australia, Amgen, Aravive, ArQule, Artios, Arvinas, AstraZeneca, AtlasMedx, BeiGene, Black Diamond, Bliss BioPharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Cascadian Therapeutics, Clovis, Compugen, Context Therapeutics, Cullinan, Curis, CytomX, Daiichi Sankyo, Dana-Farber Cancer Institute, Dantari, Deciphera, Duality Biologics, eFFECTOR Therapeutics, Eisai, Ellipses Pharma, Elucida Oncology, EMD Serono, Fochon Pharmaceuticals, Fujifilm, G1 Therapeutics, Gilead Sciences, H3 Biomedicine, Harpoon, Hutchinson MediPharma, Immunogen, Immunomedics, Incyte, Infinity Pharmaceuticals, Inspirna, InventisBio, Jacobio, Karyopharm, K-Group Beta, Kind Pharmaceuticals, Leap Therapeutics, Lilly, Loxo Oncology, Lycera, MabSpace Biosciences, MacroGenics, MedImmune, Mersana, Merus, Millennium, Molecular Templates, Myriad Genetic Laboratories, Novartis, NuCana, Olema, OncoMed, Oncothyreon, ORIC Pharmaceuticals, Orinove, Orum Therapeutics, Pfizer, PharmaMar, Pieris Pharmaceuticals, Pionyr Immunotherapeutics, Plexxikon, Prelude Therapeutics, Profound Bio, Radius Health, Regeneron, Relay Therapeutics, Repertoire Immune Medicine, Rgenix, Roche/Genentech, Seagen, Sermonix Pharmaceuticals, Shattuck Labs, Silverback Therapeutics, Stemcentrx, Stemline Therapeutics, Sutro, Syndax, Syros, Taiho, TapImmune, Tesaro, Tolmar, Torque Therapeutics, Treadwell Therapeutics, Verastem, Zenith Epigenetics, Zymeworks.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including case-based discussions of TROP2-targeted antibody drug conjugates for triple-negative breast cancer, go to https://www.gotoper.com/courses/evaluating-the-latest-data-and-ongoing-trials-for-novel-adc-approaches-in-tnbc.

Release Date

September 23, 2025

Expiration Date

September 23, 2026

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.